Posted on February 12th, 2015
by James Joyce
In my last article published on “The Chairman’s Blog,” I discussed factors underlying the increased incidence of viral epidemics, disclosed that we launched our first FDA approved clinical study and shared mechanistic details underlying our vision for treating infectious viral pathogens. Instead of deploying a drug mechanism to inhibit the replication of a single viral species, I referenced that we created the Aethlon Hemopurifier® to capture broad-spectrum circulating viruses (including many viruses not treatable with antiviral drugs) through lectin affinity attachment to a unique structure that viruses co-opt from host cells during replication. To be more specific, this unique structure resides on glycoproteins that coat the surface of infectious viruses. In well studied viruses such as HIV, it is clearly understood that virally shed glycoproteins play a role in immune suppression (the hallmark of AIDS) and perform other deleterious mechanisms to enable continued progeny virus replication. Beyond the broad-spectrum clearance of infectious viruses, an under-appreciated mechanism of Hemopurifier® therapy is its ability to capture glycoproteins once they shed from the surface of the virus.
Yesterday, the journal “Blood Purification” published a manuscript describing the first administration of Hemopurifier® therapy to an Ebola patient. The publication is entitled, “Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis.” The lead author of the publication administered Hemopurifier® therapy to an infected patient at Frankfurt University Hospital in Germany. The publication reports that 253 million copies of Ebola virus were captured within the Hemopurifier® during a single 6.5 hour treatment. Additionally, based on pre and post treatment measurements, a 63-fold reduction in viral load was observed. The paper also discusses the mechanism of the Hemopurifier® to eliminate Ebola glycoproteins, which the authors identify as decoys that neutralize antibody response and trigger lymphocyte apoptosis. The authors also report that shed glycoproteins induce a massive release of cytokines and increase vascular permeability, which in turn leads to: systemic inflammation, electrolyte disturbances, septic shock-like syndrome, multi-organ failure, and death. The article can be accessed online at: http://www.karger.com/Article/Abstract/375229
I look forward to keeping you updated on the progress of our Hemopurifier® therapy and thank you for taking the time to read this blog.
Forward Looking Statements
This blog contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary. will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2015, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.